Tumor Markers for Gastric Adenocarcinoma
For gastric adenocarcinoma, measure CEA, CA19-9, and CA125 at baseline before treatment, and monitor these markers every 1-3 months during active therapy for advanced/metastatic disease, with CEA and CA125 being the most valuable for prognosis and CA125/CA72-4 specifically useful for detecting peritoneal dissemination.
Baseline Assessment
At initial diagnosis, obtain serum levels of:
- CEA (Carcinoembryonic Antigen): Positive in 21.1% of gastric cancer cases, correlates with tumor stage and survival 1
- CA19-9: Positive in 27.8% of cases, associated with advanced stage and lymph node metastasis 1, 2
- CA125: Highest positive predictive value (72.2%) among markers, strongly associated with peritoneal dissemination 3, 1
- CA72-4: Positive in 30.0% of cases, useful for detecting peritoneal metastases 1
The combination of CEA, CA19-9, and CA72-4 provides the most effective staging information before surgery or chemotherapy 1. CEA and CA125 are independent prognostic markers with the strongest evidence for predicting survival outcomes 3.
Monitoring During Treatment
For patients with locally advanced or metastatic disease receiving active therapy:
- Measure tumor markers every 1-3 months during treatment 4
- Rising marker levels suggest disease progression but require confirmation with imaging studies 4
- Exercise caution interpreting elevations in the first 4-6 weeks of new therapy, as spurious early rises can occur 4
Key Monitoring Principles:
For elevated baseline markers: Patients with elevated pretreatment markers show higher sensitivity (73% vs 32%) for detecting recurrence compared to those with normal baseline levels 5. Monitor these patients more intensively.
For normal baseline markers: These patients have better disease-free survival (61.1% vs 42.1% at 5 years) and higher specificity (87% vs 59%) for recurrence detection 5.
Surveillance After Curative Treatment
Post-surgical monitoring strategy:
- Monitor only markers that were elevated before surgery or chemotherapy 1
- Tumor marker conversion typically occurs 2-3 months before imaging abnormalities appear 1
- Continue surveillance for at least 3 years, as most recurrences occur within this timeframe 6
Specific Clinical Scenarios:
Peritoneal metastases: CA125 and CA72-4 are most useful 3, 1. Elevated levels strongly suggest peritoneal dissemination.
Liver metastases: AFP (alpha-fetoprotein) is valuable for detecting and predicting hepatic involvement 1.
Advanced stage disease: Multiple marker elevation (≥2 markers) correlates with higher tumor burden, advanced clinical stage, and poorer differentiation 7.
Important Caveats
- Individual markers have low sensitivity for early gastric cancer (CEA: 21.1%, CA19-9: 27.8%) 1
- Not recommended for screening asymptomatic populations 4
- Markers can be falsely elevated by: bacterial cholangitis, gastritis, peptic ulcer disease, liver disease, COPD, diabetes, and acute inflammatory states 4
- Chemotherapy may transiently elevate markers, particularly CEA with oxaliplatin 4
- Approximately 5-10% of the population cannot produce CA19-9 due to Lewis antigen-negative phenotype
Prognostic Stratification
Poor prognosis indicators:
- Elevated CEA is an independent risk factor for worse outcomes 8
- Multiple marker elevation (≥2) indicates higher disease burden and poorer survival 7
- Persistently rising markers during treatment suggest progressive disease even without radiographic confirmation 4
Better prognosis indicators:
- Marker normalization after treatment correlates with improved disease-free survival similar to persistently normal patients 5
- Single marker elevation shows better progression-free survival than multiple marker elevation 7
The evidence strongly supports routine use of CEA, CA19-9, CA125, and CA72-4 in combination for gastric adenocarcinoma management, with CEA and CA125 having the strongest prognostic value based on recent systematic reviews 3, 1.